Managing bowel obstruction in patients with advanced gynecological cancers
Risk Stratified Multidisciplinary Ambulatory Management of Malignant Bowel Obstruction (MAMBO) Program for Women With Advanced Gynecological Cancers
University Health Network, Toronto · NCT03260647
This study is testing a new way to manage bowel blockages in patients with advanced gynecological cancers to see if it can improve their care while keeping them out of the hospital.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | Female |
| Sponsor | University Health Network, Toronto (other) |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT03260647 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the management of Malignant Bowel Obstruction (MBO) in patients with advanced gynecological cancers. It aims to develop a collaborative management algorithm that allows for effective treatment in an ambulatory setting, thereby optimizing patient care and resource use. By streamlining the approach to MBO, the study seeks to improve the quality and consistency of care while reducing hospital bed occupancy. The study will include patients with confirmed gynecological cancers who are at risk of or have a clinical diagnosis of MBO.
Who should consider this trial
Good fit: Ideal candidates include patients with histologically or cytologically confirmed gynecological cancers who are at risk of developing or have a clinical diagnosis of MBO.
Not a fit: Patients with gynecological cancers who do not exhibit signs of bowel obstruction may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance the quality of care for patients with advanced gynecological cancers experiencing bowel obstruction.
How similar studies have performed: While there is a lack of established guidelines for MBO management in this patient population, the collaborative approach being tested may offer novel insights into effective care.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Histologically and /or cytologically confirmed gynecological cancer, including ovarian, fallopian tube, endometrial, cervical or primary peritoneal cancer Deemed to be at risk of developing or have a clinical diagnosis of MBO as defined using the following criteria: clinical evidence of bowel obstruction (history/physical/radiological examination; and bowel obstruction beyond the ligament of Treitz. Exclusion Criteria: There are no specified exclusion criteria for this study
Where this trial is running
Toronto, Ontario
- Princess Margaret Cancer Centre — Toronto, Ontario, Canada (RECRUITING)
Study contacts
- Principal investigator: Stephanie Lheureux — University Health Network, Toronto
- Study coordinator: Stephanie L'heureux
- Email: stephanie.lheureux@uhn.ca
- Phone: 416-946-2818
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Gynecologic Cancer